ID3 mutations are recurrent events in double-hit B-cell lymphomas

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4771-4778

  Gebauer, Niklas ^a   Bernard, Veronica ^a   Feller, Alfred C ^a   Merz, Hartmut ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Double hit lymphomas; ID3; Unclassifiable B cell lymphoma

Indexed keywords

INHIBITOR OF DIFFERENTIATION 3; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CARCINOGENESIS; CHROMOSOME ABERRATION; DOUBLE HIT B CELL LYMPHOMA; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL;

DOUBLE-HIT LYMPHOMAS; ID3; UNCLASSIFIABLE B-CELL LYMPHOMA;

BURKITT LYMPHOMA; CHROMOSOME ABERRATIONS; GENE REARRANGEMENT; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; INHIBITOR OF DIFFERENTIATION PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL;

EID: 84891366824     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Akyurek N, Uner A, Benekli M and Barista I: Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 118: 4173-4183, 2012.
2. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ and Kluin PM: Double-hit B-cell lymphomas. Blood 117: 2319-2331, 2011.
3. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E and Jack A: Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28: 3360-3365, 2010.
4. Benz R and Tchinda J: Double hit, triple hit - look for it. Blood 121: 2383, 2013.
5. Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA, Myklebost O, Suo Z, Mu D, Deangelis PM and Stokke T: Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas. Leukemia 19: 2313-2323, 2005.
6. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO and Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2004.
7. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kuhn M, Lenze D, Lichter P, Martin-Subero JI, Moller P, Muller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Sturzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trumper L, Stein H and Siebert R: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419-2430, 2006.
8. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD and Horsman DE: Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114: 2273-2279, 2009.
9. Kanungo A, Medeiros LJ, Abruzzo LV, and Lin P: Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19: 25-33, 2006.
10. Li J, Maruyama T, Zhang P, Konkel JE, Hoffman V, Zamarron B and Chen W: Mutation of inhibitory helix-loop-helix protein Id3 causes gammadelta T-cell lymphoma in mice. Blood 116: 5615-5621, 2010.
11. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E and Medeiros LJ: B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21) : an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25: 145-156, 2012.
12. Lin P and Medeiros LJ: High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica 92: 1297-1301, 2007.
13. Niitsu N, Okamoto M, Miura I and Hirano M: Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23: 777-783, 2009.
14. Offit K, Wong G, Filippa DA, Tao Y and Chaganti RS: Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 77: 1508-1515, 1991.
15. Pan L, Sato S, Frederick JP, Sun XH and Zhuang Y: Impaired immune responses and B-cell proliferation in mice lacking the Id3 gene. Mol Cell Biol 19: 5969-5980, 1999.
16. Perk J, Iavarone A and Benezra R: Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 5: 603-614, 2005.
17. Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, Smith LM, Aoun P, Chan WC, Fu K, Greiner TC, Bierman P, Gregory Bociek R, Vose JM, Armitage JO and Weisenburger DD: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol 2013.
18. Pillai RK, Sathanoori M, Van Oss SB and Swerdlow SH: Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol 37: 323-332, 2013.
19. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Moller P, MacLeod RA, Pott C, Schreiber S, Trumper L, Loeffler M, Stadler PF, Lichter P, Eils R, Kuppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B and Siebert R: Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44: 1316-1320, 2012.
20. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao WM, Zhang MZ, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu XL, Powell J, Yang YD, Xu WH, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB and Staudt LM: Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490: 116-120, 2012.
21. Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ and Chen W: Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol 23: 909-920, 2010.
22. Siebert R, Rosenwald A, Staudt LM and Morris SW: Molecular features of B-cell lymphoma. Curr Opin Oncol 13: 316-324, 2001.
23. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE and Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34: 327-340, 2010.
24. Swerdlow SHea: WHO Classification of Tumors of Haematopoetic and Lymphoid Tissues: WHO, 2008.
25. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S and Leder P: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79: 7837-7841, 1982.
26. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y and Miura I: Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 94: 935-943, 2009.